Umit Tapan, MD

Clinical Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Umit Tapan is a physician-scientist who is an attending thoracic oncologist at Boston Medical Center (BMC) whose clinical interests are non-small cell lung cancer, small cell lung cancer, mesothelioma, immunotherapy and targeted therapy/precision medicine. His research interests center on reducing disparities in lung cancer treatment, improving access to new treatments. He has served as site PI at BMC for 16 therapeutic trials and currently manages seven active protocols funded by the National Cancer Institute and industry partners. Since 2019, he has served as co-director of the Thoracic Oncology Program within the BU-BMC Cancer Center, and in 2020 he was appointed director of inpatient medical operations for the section of hematology and medical oncology.

Publications

  • Published 8/5/2026

    Herrera VLM, Mahdaviani K, Choi J, Chen SH, Gunn E, Stadnicki K, Mortazavi-Zadeh A, Lok JJ, Tapan U, Ruiz-Opazo N. Prospective subtyping identifies an association between high pretreatment levels of DEspR+ neutrophil extracellular trap-forming neutrophils and microvesicles during sterile inflammation with poor survival in patients with metastatic non-small cell lung cancer receiving first-line combination chemo-immunotherapy. Front Immunol. 2026; 17:1849858. PMID: 42620556.

    Read at: PubMed

  • Published 6/30/2026

    Dirnberger F, Patel S, Boyne DJ, Lan Z, Uyei J, Wang J, Cho S, DeCosta L, Bridges IM, Tapan U. Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer. Adv Ther. 2026 Sep; 43(9):4282-4298. PMID: 42377743.

    Read at: PubMed

  • Published 6/18/2026

    Ferri GM, Murphy JF, Oza A, Bulteel AJB, Abbasi W, Anderson R, Dinc MT, Gaufberg E, Cengiz K, Sontha S, Weinberg J, Kurpaska P, Mangala YO, Kulke M, Tapan U. Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience. Ecancermedicalscience. 2026; 20:2150. PMID: 42453165.

    Read at: PubMed

  • Published 5/20/2026

    Hill NR, Crosbie A, Szymialis R, Botros A, Zhang Y, Tapan U. Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer. J Oncol Pharm Pract. 2026 May 20; 10781552261449764. PMID: 42159393.

    Read at: PubMed

  • Published 3/10/2026

    Kim JY, Dirks A, Ford RM, Pai L, Ludwig C, Tapan U. How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups. PLOS Digit Health. 2026 Mar; 5(3):e0001262. PMID: 41805924.

    Read at: PubMed

View All 47 Publications:   View Full Profile in BUMC

Other Positions

  • Member, BU-BMC Cancer Center
    Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University

Websites

Education

  • Hacettepe University, MD

View all profiles